Abstract: This invention provides a substrate solution for measuring lipase activity, a reagent for measuring lipase activity, and an emulsion solution excellent in storage stability. This invention also provides a method for measuring lipase activity in a sample that enables accurate measurement over a long period of time. This invention further provides a method for improving storage stability of a substrate solution for measuring lipase activity and an emulsion solution. To this end, a substrate solution for measuring lipase activity comprising the emulsion solution comprising micelle particles of 1,2-o-dilauryl-rac-glycero-3-glutaric acid (6?-methylresorufin) ester and side-chain-type nonreactive polyether-modified-type modified silicone oil is used.

Abstract: Provided is a process for producing a substrate solution for measuring lipase activity including, as a substrate for measuring lipase activity, 1,2-o-dilauryl-rac-glycero-3-glutaric acid (6?-methylresorufin) ester, wherein the production process does not necessitate cumbersome or special processing such that skill is required, or does not necessitate a special apparatus, instruments, or other items. This production process is a process for producing a substrate solution for measuring lipase activity, and is characterized by including the steps of (1) mixing the substrate for measuring lipase activity and a side-chain-type nonreactive polyether-modified-type modified silicone oil or a polyoxyethylene/polyoxypropylene condensate to prepare a mixture, and (2) mixing all or a portion of the mixture of step (1) with water or an aqueous solution.

Abstract: This invention provides a substrate solution for measuring lipase activity, a reagent for measuring lipase activity, and an emulsion solution excellent in storage stability. This invention also provides a method for measuring lipase activity in a sample that enables accurate measurement over a long period of time. This invention further provides a method for improving storage stability of a substrate solution for measuring lipase activity and an emulsion solution. To this end, a substrate solution for measuring lipase activity comprising the emulsion solution comprising micelle particles of 1,2-o-dilauryl-rac-glycero-3-glutaric acid (6?-methylresorufin) ester and side-chain-type nonreactive polyether-modified-type modified silicone oil is used.

Abstract: Provided is a process for producing a substrate solution for measuring lipase activity including, as a substrate for measuring lipase activity, 1,2-o-dilauryl-rac-glycero-3-glutaric acid (6?-methylresorufin) ester, wherein the production process does not necessitate cumbersome or special processing such that skill is required, or does not necessitate a special apparatus, instruments, or other items. This production process is a process for producing a substrate solution for measuring lipase activity, and is characterized by including the steps of (1) mixing the substrate for measuring lipase activity and a side-chain-type nonreactive polyether-modified-type modified silicone oil or a polyoxyethylene/polyoxypropylene condensate to prepare a mixture, and (2) mixing all or a portion of the mixture of step (1) with water or an aqueous solution.

Abstract: The present invention provides a method and a reagent for measuring periostin contained in a sample with improved accuracy, a method for improving accuracy in measurement of periostin, and a method of testing for pulmonary fibrosis or interstitial pneumonia with improved accuracy. The antibody of the present invention binds to at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin or a cleavage product thereof. The method and the reagent for measuring periostin and the method for improving accuracy in periostin measurement of the present invention is characterized by detecting at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin.

Abstract: The present invention provides a method and a reagent for measuring periostin contained in a sample with improved accuracy, a method for improving accuracy in measurement of periostin, and a method of testing for pulmonary fibrosis or interstitial pneumonia with improved accuracy. The antibody of the present invention binds to at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin or a cleavage product thereof. The method and the reagent for measuring periostin and the method for improving accuracy in periostin measurement of the present invention is characterized by detecting at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin.

Abstract: The present invention provides a method and a reagent for measuring periostin contained in a sample with improved accuracy, a method for improving accuracy in measurement of periostin, and a method of testing for pulmonary fibrosis or interstitial pneumonia with improved accuracy. The antibody of the present invention binds to at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin or a cleavage product thereof. The method and the reagent for measuring periostin and the method for improving accuracy in periostin measurement of the present invention is characterized by detecting at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin.

Abstract: Previously, it was difficult to obtain high-affinity antibodies that specifically bind to HMGB-1 but not to HMGB-2. Under this circumstance, the present inventors successfully obtained antibodies that are more reactive to HMGB-1 than to HMGB-2 by using specific peptides as an antigen. The present inventors also demonstrated that the antibodies had a HMGB-1-neutralizing activity. The present inventors administered the antibodies to amyloidosis model animals, and as a result, successfully demonstrated that the antibodies produced a significant therapeutic effect.

Abstract: Previously, it was difficult to obtain high-affinity antibodies that specifically bind to HMGB-1 but not to HMGB-2. Under this circumstance, the present inventors successfully obtained antibodies that are more reactive to HMGB-1 than to HMGB-2 by using specific peptides as an antigen. The present inventors also demonstrated that the antibodies had a HMGB-1-neutralizing activity. The present inventors administered the antibodies to amyloidosis model animals, and as a result, successfully demonstrated that the antibodies produced a significant therapeutic effect.

Abstract: The present invention is a blood coagulation reaction inhibitor comprising phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. The present invention is also a thrombin generation inhibitor comprising phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. The blood coagulation reaction inhibitor and the thrombin generation inhibitor of the present invention are useful as an antithrombotic agent, a clinical laboratory test reagent for the blood coagulation-fibrinolysis system, and the like.

Abstract: Previously, it was difficult to obtain high-affinity antibodies that specifically bind to HMGB-1 but not to HMGB-2. Under this circumstance, the present inventors successfully obtained antibodies that are more reactive to HMGB-1 than to HMGB-2 by using specific peptides as an antigen. The present inventors also demonstrated that the antibodies had a HMGB-1-neutralizing activity. The present inventors administered the antibodies to amyloidosis model animals, and as a result, successfully demonstrated that the antibodies produced a significant therapeutic effect.

Abstract: An objective of the present invention is to provide effective methods for treating interstitial pulmonary diseases including interstitial pneumonia such as IPF. The present invention suggests that antibodies against HMGB-1 are effective for treating pulmonary fibrosis. Thus, the present invention provides preparations which comprise an anti-HMGB-1 antibody for treating interstitial pulmonary diseases.

Abstract: An objective of the present invention is to provide effective methods for suppressing rejection in organ transplantation, in particular, pancreatic islet transplantation which is useful in treating diabetes. The present invention demonstrated that antibodies against HMGB-1 suppressed the rejection in pancreatic islet transplantation and promoted the survival of grafted pancreatic islets. Thus, the present invention provides agents that comprise an anti-HMGB-1 antibody for suppressing rejection in organ transplantation.

Abstract: An object of the present invention is to provide an anti-human HMGB1 antibody having high capability of binding to human high mobility group box protein-1 (HMGB1) with a high probability. According to the present invention, a highly sensitive immunoassay method and immunoassay reagent for human HMGB1 in a sample using the anti-human HMGB1 antibody are provided. Specifically, provided herein are: an avian-derived anti-human HMGB1 antibody specifically binding to the amino acid sequence shown by the following formula (I): Lys Pro Asp Ala Ala Lys Lys Gly Val Val Lys Ala Glu Lys Ser (I) of human HMGB1; and an immunoassay method and an immunoassay reagent for human HMGB1 in a sample, which are characterized by using the antibody.

Abstract: The present invention is a method for calorimetrically determining a metal in a sample using a chelating coloring agent, characterized by coexistence of a masking agent for iron, copper or nickel. Also, the present invention is a reagent for calorimetrically determining a metal in a sample using a chelating coloring agent, characterized by inclusion of a masking agent for iron, copper and/or nickel. Further, the present invention is a masking agent for iron, copper and/or nickel and a method for reducing positive errors due to iron, copper or nickel contained in a sample.

Abstract: The present invention relates to a reagent for selective measurement of triglycerides contained in very low density lipoprotein and intermediate density lipoprotein or in very low density lipoprotein in a test sample, including a first reagent that contains a first selective reaction promoter, which is an ether or ester compound of a polyoxyalkylene capable of reacting lipoprotein lipase selectively with triglycerides contained in low density lipoprotein and high density lipoprotein; lipoprotein lipase; enzymes which catalyze a series of reactions leading to the generation of hydrogen peroxide or a reduced coenzyme from glycerol; and an enzyme which catalyzes a reaction leading to the conversion of hydrogen peroxide or a reduced coenzyme into another substance, and a second reagent that contains a second selective reaction promoter, which is capable of reacting lipoprotein lipase selectively with triglycerides contained in very low density lipoprotein, intermediate density lipoprotein, low density lipoprotein

Abstract: Amino acid sequences having specificity as lipoprotein (a) and low homology with LDL and plasminogen are selected from the amino acid sequence of lipoprotein (a), and antibodies to lipoprotein (a) which recognize these amino acid sequences specifically are obtained. At least one of these antibodies is used in immunological techniques for the determination of lipoprotein (a). Moreover, an amino acid sequence having specificity as apolipoprotein (a) and not having antigenicity as lipoprotein (a) or plasminogen is selected from the amino acid sequence of apolipoprotein (a), and antibodies to apolipoprotein (a) which recognize this amino acid sequence specifically are obtained. At least one of these antibodies is used in immunological techniques for the determination of apolipoprotein (a).